GB2279077B - Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha - Google Patents

Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha

Info

Publication number
GB2279077B
GB2279077B GB9415380A GB9415380A GB2279077B GB 2279077 B GB2279077 B GB 2279077B GB 9415380 A GB9415380 A GB 9415380A GB 9415380 A GB9415380 A GB 9415380A GB 2279077 B GB2279077 B GB 2279077B
Authority
GB
United Kingdom
Prior art keywords
tnfalpha
antibodies specific
therapeutic compositions
recombinant antibodies
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB9415380A
Other versions
GB9415380D0 (en
GB2279077A (en
Inventor
Mark William Bodmer
John Spencer Emtage
Diljeet Singh Athwal
John Robert Adair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/GB1990/002017 priority Critical patent/WO1991009967A1/en
Priority to GB9109645A priority patent/GB9109645D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Priority to GB9217880A priority patent/GB2257145B/en
Publication of GB9415380D0 publication Critical patent/GB9415380D0/en
Publication of GB2279077A publication Critical patent/GB2279077A/en
Application granted granted Critical
Publication of GB2279077B publication Critical patent/GB2279077B/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
GB9415380A 1989-12-21 1991-12-20 Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha Expired - Lifetime GB2279077B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/GB1990/002017 WO1991009967A1 (en) 1989-12-21 1990-12-21 Humanised antibodies
GB9109645A GB9109645D0 (en) 1991-05-03 1991-05-03 Recombinant antibodies
GB9217880A GB2257145B (en) 1990-12-21 1991-12-20 Recombinant antibodies specific for TNFalpha

Publications (3)

Publication Number Publication Date
GB9415380D0 GB9415380D0 (en) 1994-09-21
GB2279077A GB2279077A (en) 1994-12-21
GB2279077B true GB2279077B (en) 1995-06-14

Family

ID=26298838

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9415380A Expired - Lifetime GB2279077B (en) 1989-12-21 1991-12-20 Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha

Country Status (1)

Country Link
GB (1) GB2279077B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8197813B2 (en) 1996-02-09 2012-06-12 Abbott Biotechnology Ltd. Human antibodies that bind human TNFα
US8206714B2 (en) 1996-02-09 2012-06-26 Abbott Biotechnology Ltd. Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa
US8231876B2 (en) 2006-04-05 2012-07-31 Abbott Biotechnology Ltd. Purified antibody composition
US8715664B2 (en) 2005-05-16 2014-05-06 Abbvie Biotechnology Ltd. Use of human TNFα antibodies for treatment of erosive polyarthritis
US8846046B2 (en) 2002-10-24 2014-09-30 Abbvie Biotechnology Ltd. Low dose methods for treating disorders in which TNFα activity is detrimental
US8889136B2 (en) 2004-04-09 2014-11-18 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
CN101802005B (en) 2007-08-28 2015-09-16 艾伯维生物技术有限公司 The compositions and methods comprising a protein bound on the adalimumab
CN101969929B (en) 2008-01-15 2014-07-30 Abbvie德国有限责任两合公司 Powdered protein compositions and methods of making same
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
KR20150043523A (en) 2012-09-02 2015-04-22 애브비 인코포레이티드 Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
EP0380068A1 (en) * 1989-01-24 1990-08-01 Miles Inc. An expression system for production of chimeric monoclonal antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
EP0380068A1 (en) * 1989-01-24 1990-08-01 Miles Inc. An expression system for production of chimeric monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.Cell.Biochem.Suppl. 1989,0(13 Part A),96,Abs.A342 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8197813B2 (en) 1996-02-09 2012-06-12 Abbott Biotechnology Ltd. Human antibodies that bind human TNFα
US8206714B2 (en) 1996-02-09 2012-06-26 Abbott Biotechnology Ltd. Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa
US8753633B2 (en) 1996-02-09 2014-06-17 Abbvie Biotechnology Ltd. Human antibodies that bind human TNFα
US8372400B2 (en) 1996-02-09 2013-02-12 Abbott Biotechnology Ltd. Methods of treating disorders using human antibodies that bind human TNFα
US8372401B2 (en) 1996-02-09 2013-02-12 Abbott Biotechnology Ltd. Human antibodies that bind human TNFα
US8414894B2 (en) 1996-02-09 2013-04-09 Abbott Biotechnology Ltd. Human antibodies that bind human TNFα and methods of using same
US8906373B2 (en) 2002-07-19 2014-12-09 Abbvie Biotechnology Ltd. Use of TNF-alpha inhibitor for treatment of psoriasis
US8846046B2 (en) 2002-10-24 2014-09-30 Abbvie Biotechnology Ltd. Low dose methods for treating disorders in which TNFα activity is detrimental
US9187559B2 (en) 2004-04-09 2015-11-17 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US8961973B2 (en) 2004-04-09 2015-02-24 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8961974B2 (en) 2004-04-09 2015-02-24 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8889136B2 (en) 2004-04-09 2014-11-18 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8986693B1 (en) 2004-04-09 2015-03-24 Abbvie Biotechnology Ltd. Use of TNFα inhibitor for treatment of psoriasis
US9499615B2 (en) 2004-04-09 2016-11-22 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US8808700B1 (en) 2005-05-16 2014-08-19 Abbvie Biotechnology Ltd. Use of TNF alpha inhibitor for treatment of erosive polyarthritis
US8715664B2 (en) 2005-05-16 2014-05-06 Abbvie Biotechnology Ltd. Use of human TNFα antibodies for treatment of erosive polyarthritis
US8906372B2 (en) 2006-04-05 2014-12-09 Abbvie Biotechnology Ltd. Purified antibody composition
US8916153B2 (en) 2006-04-05 2014-12-23 Abbvie Biotechnology Ltd. Purified antibody composition
US8883156B2 (en) 2006-04-05 2014-11-11 Abbvie Biotechnology Ltd. Purified antibody composition
US9096666B2 (en) 2006-04-05 2015-08-04 Abbvie Biotechnology Ltd Purified antibody composition
US9102723B2 (en) 2006-04-05 2015-08-11 Abbvie Biotechnology Ltd Purified antibody composition
US8231876B2 (en) 2006-04-05 2012-07-31 Abbott Biotechnology Ltd. Purified antibody composition
US8895009B2 (en) 2006-04-05 2014-11-25 Abbvie Biotechnology Ltd. Purified antibody composition
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα

Also Published As

Publication number Publication date
GB2279077A (en) 1994-12-21
GB9415380D0 (en) 1994-09-21

Similar Documents

Publication Publication Date Title
GB2242806B (en) Handover techniques
GB2242805B (en) Handover techniques
KR960014778B1 (en) Shampoo composition
GB2246781B (en) CD3 specific recombinant antibody
GB2249310B (en) Antibody preparation
GB2235925B (en) Photocurable compositions
PT100735A (en) Recombinant antibodies for human therapy
GB9013750D0 (en) Therapeutic agents
GB9221657D0 (en) Recombinant bispecific antibodies
ZA8301463B (en) Antibody conjugates
EP0088695A3 (en) Antibody conjugates
HK1013319A1 (en) Waterproofing material
EP0323805A3 (en) Novel antibodies
GB9113477D0 (en) Counterbalanced reciprocating mechanism
IL97313D0 (en) 3-arylcarbonyl-1h-indoles useful as therapeutic agents
GB9113758D0 (en) Counterbalanced reciprocating mechanism
ZA9103282B (en) Dosage form
GB9012533D0 (en) Glass composition
GR3026588T3 (en) PURIFIED IgG ANTIBODIES
EP0784469A4 (en) Compositions for the delivery of antigens
GB8905669D0 (en) Modified antibodies
GB9115761D0 (en) Shampoo composition
EP0439095A3 (en) Therapeutic antibody based fusion proteins
HU910695D0 (en) Composition co-extrusible with polyfluoro-vinylidene
GB9027638D0 (en) Cable-sealing mastic material

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20111219